金沙06优惠活动申请大厅(官方认证)-正版Application program

Be the most trusted biotech company

2024-05-15

First Patient Dosed for MRCT Phase 3 Study on First-Line mCRC of Henlius Anti-PD-1 mAb Serplulimab
2024-05-14

Henlius lasofoxifene HLX78 IND Approved by NMPA
2024-05-10

Henlius Holds its first Scientific Advisory Board Meeting of 2024
2024-05-06

Henlius Dual HER2 Blockade Therapy Receives Phase 3 MRCT IND Approval from U.S. FDA
2024-04-29

Henlius maintained a positive momentum of development in Q1 2024, with impressive performances by core products
2024-04-26

Henlius Trastuzumab Receives FDA Approval in the United States
2024-04-25

Henlius to Showcase Latest Results of Serplulimab at 2024 ASCO
2024-04-23

First Subject Dosed for Phase 1 Clinical Trial of Henlius’ Novel Anti-GARP/TGF-β1 mAb HLX6018
2024-04-17

IND Application for the Clinical Trial of Novel Anti-TIGIT Fc Fusion Protein HLX53 in Combination with HANSIZHUANG Plus HANBEITAI for the First-Line Treatment of Locally Advanced or Metastatic Hepatocellular Carcinoma Patients Approved by NMPA